{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T14:00:21Z","timestamp":1790085621848,"version":"4.0.1"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T00:00:00Z","timestamp":1787788800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006342","name":"Defeating Cystic Fibrosis Association","doi-asserted-by":"publisher","award":["RF20230503290"],"award-info":[{"award-number":["RF20230503290"]}],"id":[{"id":"10.13039\/501100006342","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine & Pharmacotherapy"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.biopha.2026.119892","type":"journal-article","created":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T22:40:15Z","timestamp":1788561615000},"page":"119892","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Microbial modulation of CFTR modulator exposure: In vitro interactions between elexacaftor-tezacaftor-ivacaftor and pulmonary and gut bacteria from people with cystic fibrosis"],"prefix":"10.1016","volume":"203","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-6315-9502","authenticated-orcid":false,"given":"Pierrick","family":"Boulic","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0697-4370","authenticated-orcid":false,"given":"Cyril","family":"Leven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danni","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yimin","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliana Alcoforado","family":"Diniz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phanie","family":"Gouriou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6044-4824","authenticated-orcid":false,"given":"Elena K.","family":"Schneider-Futschik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Genevi\u00e8ve","family":"H\u00e9ry-Arnaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10059","key":"10.1016\/j.biopha.2026.119892_bib1","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1016\/S0140-6736(16)00576-6","article-title":"Cystic fibrosis","volume":"388","author":"Elborn","year":"2016","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.biopha.2026.119892_bib2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40348-016-0067-1","article-title":"Acquisition and adaptation of the airway microbiota in the early life of cystic fibrosis patients","volume":"4","author":"Boutin","year":"2017","journal-title":"Mol. Cell. Pediatr."},{"issue":"4","key":"10.1016\/j.biopha.2026.119892_bib3","doi-asserted-by":"crossref","DOI":"10.1128\/msphere.00046-23","article-title":"Development of the intestinal microbiome in cystic fibrosis in early life","volume":"8","author":"Price","year":"2023","journal-title":"mSphere"},{"issue":"1","key":"10.1016\/j.biopha.2026.119892_bib4","doi-asserted-by":"crossref","first-page":"6845","DOI":"10.1038\/s41598-021-85592-w","article-title":"An observational study of anaerobic bacteria in cystic fibrosis lung using culture-dependent and culture-independent approaches","volume":"11","author":"Lamoureux","year":"2021","journal-title":"Sci. Rep."},{"issue":"5","key":"10.1016\/j.biopha.2026.119892_bib5","doi-asserted-by":"crossref","first-page":"536","DOI":"10.3390\/genes11050536","article-title":"The microbiome in cystic fibrosis pulmonary disease","volume":"11","author":"Fran\u00e7oise","year":"2020","journal-title":"Genes (Basel)"},{"issue":"10290","key":"10.1016\/j.biopha.2026.119892_bib6","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1016\/S0140-6736(20)32542-3","article-title":"Cystic fibrosis","volume":"397","author":"Shteinberg","year":"2021","journal-title":"Lancet"},{"issue":"10212","key":"10.1016\/j.biopha.2026.119892_bib7","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1016\/S0140-6736(19)32597-8","article-title":"Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial","volume":"394","author":"Heijerman","year":"2019","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.biopha.2026.119892_bib8","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/j.jcf.2025.03.008","article-title":"Real-world pharmacokinetics of elexacaftor-tezacaftor-ivacaftor in children with cystic fibrosis: a prospective observational study","volume":"24","author":"Vonk","year":"2025","journal-title":"J. Cyst. Fibros."},{"issue":"6","key":"10.1016\/j.biopha.2026.119892_bib9","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1016\/j.jcf.2024.04.013","article-title":"Heterogeneity in response to elexacaftor\/tezacaftor\/ivacaftor in people with cystic fibrosis","volume":"23","author":"Alicandro","year":"2024","journal-title":"J. Cyst. Fibros."},{"issue":"26","key":"10.1016\/j.biopha.2026.119892_bib10","first-page":"00060","article-title":"Contributors to the heterogeneity of response to CFTR modulators","volume":"S2213-2600","author":"Downey","year":"2026","journal-title":"Lancet Respir. Med."},{"issue":"17","key":"10.1016\/j.biopha.2026.119892_bib11","doi-asserted-by":"crossref","first-page":"13384","DOI":"10.3390\/ijms241713384","article-title":"Modulation of plasmatic matrix metalloprotease 9: a promising new tool for understanding the variable clinical responses of patients with cystic fibrosis to CFTR modulators","volume":"24","author":"Capraro","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.biopha.2026.119892_bib12","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.577263","article-title":"Insights into patient variability during ivacaftor-lumacaftor therapy in cystic fibrosis","volume":"12","author":"Hanafin","year":"2021","journal-title":"Front. Pharmacol."},{"issue":"1","key":"10.1016\/j.biopha.2026.119892_bib13","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-025-64218-z","article-title":"CFTR modulator therapy drives microbiome restructuring through improved host physiology in cystic fibrosis: the IMMProveCF phase IV trial","volume":"16","author":"Knoll","year":"2025","journal-title":"Nat. Commun."},{"issue":"4","key":"10.1016\/j.biopha.2026.119892_bib14","article-title":"The impact of cystic fibrosis transmembrane conductance regulator modulators on the pulmonary microbiota","volume":"171","author":"Robertson","year":"2025","journal-title":"Microbiol. (Read. )"},{"issue":"174","key":"10.1016\/j.biopha.2026.119892_bib15","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0068-2024","article-title":"Changing profile of bacterial infection and microbiome in cystic fibrosis: when to use antibiotics in the era of CFTR-modulator therapy","volume":"33","author":"Milczewska","year":"2024","journal-title":"Eur. Respir. Rev."},{"issue":"5","key":"10.1016\/j.biopha.2026.119892_bib16","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/j.jcf.2024.05.002","article-title":"Impact of extended elexacaftor\/tezacaftor\/ivacaftor therapy on the gut microbiome in cystic fibrosis","volume":"23","author":"Marsh","year":"2024","journal-title":"J. Cyst. Fibros."},{"issue":"7","key":"10.1016\/j.biopha.2026.119892_bib17","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1021\/acsinfecdis.6b00035","article-title":"An \u2018unlikely\u2019 pair: the antimicrobial synergy of polymyxin B in combination with the cystic fibrosis transmembrane conductance regulator drugs KALYDECO and ORKAMBI","volume":"2","author":"Schneider","year":"2016","journal-title":"ACS Infect. Dis."},{"issue":"5","key":"10.1016\/j.biopha.2026.119892_bib18","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.jcf.2014.02.004","article-title":"Antibacterial properties of the CFTR potentiator ivacaftor","volume":"13","author":"Reznikov","year":"2014","journal-title":"J. Cyst. Fibros."},{"issue":"1","key":"10.1016\/j.biopha.2026.119892_bib19","doi-asserted-by":"crossref","DOI":"10.1128\/spectrum.04083-22","article-title":"Mutual effects of single and combined CFTR modulators and bacterial infection in cystic fibrosis","volume":"11","author":"Cigana","year":"2023","journal-title":"Microbiol. Spectr."},{"issue":"3","key":"10.1016\/j.biopha.2026.119892_bib20","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1021\/acsptsci.0c00030","article-title":"Metabolomic description of ivacaftor elevating polymyxin B-mediated antibacterial activity in cystic fibrosis Pseudomonas aeruginosa","volume":"3","author":"Allobawi","year":"2020","journal-title":"ACS Pharmacol. Transl. Sci."},{"issue":"8","key":"10.1016\/j.biopha.2026.119892_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2024.107594","article-title":"Drug metabolism of ciprofloxacin, ivacaftor, and raloxifene by Pseudomonas aeruginosa cytochrome P450 CYP107S1","volume":"300","author":"Kandel","year":"2024","journal-title":"J. Biol. Chem."},{"issue":"6","key":"10.1016\/j.biopha.2026.119892_bib22","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1007\/s40262-025-01516-1","article-title":"Population pharmacokinetics of elexacaftor, tezacaftor and ivacaftor in a real-world cohort of adults with cystic fibrosis","volume":"64","author":"Magnas","year":"2025","journal-title":"Clin. Pharmacokinet."},{"issue":"5","key":"10.1016\/j.biopha.2026.119892_bib23","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0127742","article-title":"Pseudomonas aeruginosa reduces VX-809-stimulated F508del-CFTR chloride secretion by airway epithelial cells","volume":"10","author":"Stanton","year":"2015","journal-title":"PLoS. One"},{"key":"10.1016\/j.biopha.2026.119892_bib24","doi-asserted-by":"crossref","first-page":"470","DOI":"10.3389\/fcimb.2017.00470","article-title":"Quorum sensing down-regulation counteracts the negative impact of Pseudomonas aeruginosa on CFTR channel expression, function and rescue in human airway epithelial cells","volume":"7","author":"Maill\u00e9","year":"2017","journal-title":"Front. Cell. Infect. Microbiol."},{"issue":"3","key":"10.1016\/j.biopha.2026.119892_bib25","doi-asserted-by":"crossref","first-page":"00970-2024","DOI":"10.1183\/23120541.00970-2024","article-title":"Deleterious effect of Pseudomonas aeruginosa on F508del-CFTR rescued by elexacaftor\/tezacaftor\/ivacaftor is clinical strain-dependent in patient-derived nasal cells","volume":"11","author":"Allegretta","year":"2025","journal-title":"ERJ Open. Res."},{"issue":"1","key":"10.1016\/j.biopha.2026.119892_bib26","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1757-4749-4-16","article-title":"Gut pharmacomicrobiomics: the tip of an iceberg of complex interactions between drugs and gut-associated microbes","volume":"4","author":"Saad","year":"2012","journal-title":"Gut Pathog."},{"issue":"10","key":"10.1016\/j.biopha.2026.119892_bib27","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1080\/17425247.2023.2233900","article-title":"Targeting the gut microbiome to control drug pharmacomicrobiomics: the next frontier in oral drug delivery","volume":"20","author":"Kamath","year":"2023","journal-title":"Expert. Opin. Drug. Deliv."},{"issue":"3","key":"10.1016\/j.biopha.2026.119892_bib28","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1124\/dmd.118.084772","article-title":"Commensal gut bacteria convert the immunosuppressant tacrolimus to less potent metabolites","volume":"47","author":"Guo","year":"2019","journal-title":"Drug. Metab. Dispos."},{"issue":"6445","key":"10.1016\/j.biopha.2026.119892_bib29","doi-asserted-by":"crossref","DOI":"10.1126\/science.aau6323","article-title":"Discovery and inhibition of an interspecies gut bacterial pathway for levodopa metabolism","volume":"364","author":"Maini Rekdal","year":"2019","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.biopha.2026.119892_bib30","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1038\/s41392-023-01619-w","article-title":"Drug-microbiota interactions: an emerging priority for precision medicine","volume":"8","author":"Zhao","year":"2023","journal-title":"Signal. Transduct. Target. Ther."},{"issue":"3","key":"10.1016\/j.biopha.2026.119892_bib31","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.ijantimicag.2017.03.020","article-title":"Repurposing ivacaftor for treatment of Staphylococcus aureus infections","volume":"50","author":"Thakare","year":"2017","journal-title":"Int. J. Antimicrob. Agents"},{"issue":"6","key":"10.1016\/j.biopha.2026.119892_bib32","doi-asserted-by":"crossref","DOI":"10.1093\/jacamr\/dlae185","article-title":"Evaluating the effects of ivacaftor exposure on Staphylococcus aureus small colony variant development and antibiotic tolerance","volume":"6","author":"Bollar","year":"2024","journal-title":"JAC Antimicrob. Resist."},{"issue":"5","key":"10.1016\/j.biopha.2026.119892_bib33","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1021\/acsptsci.0c00103","article-title":"Multiple reaction monitoring mass spectrometry for the drug monitoring of ivacaftor, tezacaftor, and elexacaftor treatment response in cystic fibrosis: a high-throughput method","volume":"3","author":"Reyes-Ortega","year":"2020","journal-title":"ACS Pharmacol. Transl. Sci."},{"issue":"7","key":"10.1016\/j.biopha.2026.119892_bib34","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1016\/j.foodres.2007.01.012","article-title":"The logistic (Verhulst) model for sigmoid microbial growth curves revisited","volume":"40","author":"Peleg","year":"2007","journal-title":"Food Res. Int."},{"issue":"2","key":"10.1016\/j.biopha.2026.119892_bib35","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1002\/wics.199","article-title":"The Bayesian information criterion: background, derivation, and applications","volume":"4","author":"Neath","year":"2012","journal-title":"Wiley Interdiscip. Rev. Comput. Stat."},{"key":"10.1016\/j.biopha.2026.119892_bib36","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.ijid.2023.11.013","article-title":"Use of elexacaftor\/tezacaftor\/ivacaftor leads to changes in detection frequencies of Staphylococcus aureus and Pseudomonas aeruginosa dependent on age and lung function in people with cystic fibrosis","volume":"139","author":"Dittrich","year":"2024","journal-title":"Int. J. Infect. Dis."},{"issue":"6","key":"10.1016\/j.biopha.2026.119892_bib37","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1016\/j.jcf.2025.08.019","article-title":"Factors associated with sustained Pseudomonas aeruginosa infection following elexacaftor\/tezacaftor\/ivacaftor treatment: real-world data from the European Cystic Fibrosis Society Patient Registry","volume":"24","author":"Pollak","year":"2025","journal-title":"J. Cyst. Fibros."},{"issue":"1","key":"10.1016\/j.biopha.2026.119892_bib38","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1086\/514623","article-title":"Pharmacodynamics of fluoroquinolones","volume":"27","author":"Lode","year":"1998","journal-title":"Clin. Infect. Dis."},{"issue":"9","key":"10.1016\/j.biopha.2026.119892_bib39","doi-asserted-by":"crossref","first-page":"a025320","DOI":"10.1101\/cshperspect.a025320","article-title":"Topoisomerase inhibitors: fluoroquinolone mechanisms of action and resistance","volume":"6","author":"Hooper","year":"2016","journal-title":"Cold Spring Harb. Perspect. Med."},{"issue":"11","key":"10.1016\/j.biopha.2026.119892_bib40","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1002\/ppul.26093","article-title":"Plasma and cellular ivacaftor concentrations in patients with cystic fibrosis","volume":"57","author":"Guimbellot","year":"2022","journal-title":"Pediatr. Pulmonol."},{"issue":"5","key":"10.1016\/j.biopha.2026.119892_bib41","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1016\/j.jcf.2020.04.010","article-title":"Accumulation and persistence of ivacaftor in airway epithelia with prolonged treatment","volume":"19","author":"Guhr Lee","year":"2020","journal-title":"J. Cyst. Fibros."},{"issue":"22","key":"10.1016\/j.biopha.2026.119892_bib42","doi-asserted-by":"crossref","first-page":"8079","DOI":"10.1128\/JB.01138-07","article-title":"Nutritional cues control Pseudomonas aeruginosa multicellular behavior in cystic fibrosis sputum","volume":"189","author":"Palmer","year":"2007","journal-title":"J. Bacteriol."},{"issue":"1","key":"10.1016\/j.biopha.2026.119892_bib43","doi-asserted-by":"crossref","DOI":"10.1128\/jb.00286-23","article-title":"An in vitro medium for modeling gut dysbiosis associated with cystic fibrosis","volume":"206","author":"Barrack","year":"2024","journal-title":"J. Bacteriol."},{"issue":"3","key":"10.1016\/j.biopha.2026.119892_bib44","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1111\/bph.13365","article-title":"Low free drug concentration prevents inhibition of F508del-CFTR functional expression by the potentiator VX-770 (ivacaftor)","volume":"173","author":"Matthes","year":"2016","journal-title":"Br. J. Pharmacol."}],"container-title":["Biomedicine & Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332226009285?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332226009285?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T13:07:23Z","timestamp":1790082443000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332226009285"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":44,"alternative-id":["S0753332226009285"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2026.119892","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Microbial modulation of CFTR modulator exposure: In vitro interactions between elexacaftor-tezacaftor-ivacaftor and pulmonary and gut bacteria from people with cystic fibrosis","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2026.119892","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"119892"}}